AzTrials
AzTrials

Urinary Bladder DiseasesPhase 3BESIDENCT01908829

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

A Phase 3 study testing mirabegron 25 mg, mirabegron 50 mg and solifenacin 5 mg in people with Urinary Bladder Diseases and Urinary Bladder Overactive, run by Astellas Pharma Europe Ltd. at 219 sites in 31 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
mirabegron 25 mg, mirabegron 50 mg and solifenacin 5 mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
2,174 participants
Where
219 sitesin 31 countries
Study dates
10 Jul 2013to 25 Nov 2014
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Main Inclusion at Screening:
  • Subject has symptoms of OAB (urinary frequency and urgency with urgency incontinence) for >= 3 months prior to the screening visit
  • Subject is willing and able to complete the micturition diary and questionnaires correctly, including collection and measurement of urine output for 3 days prior to each visit;
  • Subject has symptoms of "wet" OAB (urinary frequency and urgency with incontinence or mixed incontinence with predominant urgency incontinence), and reports an average of at least 2 incontinence episodes per day.
  • Main Inclusion at Run-in (Visit 2):
  • Subject experiences on average at least 1 episode of urgency (grade 3 or 4) with or without incontinence per 24-hour period during the 3-day micturition diary period.
Show all 10Show fewer
  • Subject experiences on average at least 2 incontinence episodes per 24-hour period during the 3-day micturition diary period.
  • Subject experiences on average at least 8 micturitions (excluding incontinence episodes) per 24-hour period during the 3-day micturition diary period.
  • Main Inclusion at Randomization (Visit 3):
  • Subject experiences at least 1 incontinence episode during the 3-day micturition diary period and wishes to increase their treatment for OAB symptoms.

Who cannot join

  • Main Exclusion at Screening:
  • Subject in the opinion of the investigator has clinically significant Bladder Outlet Obstruction (BOO).
  • Subject has significant Post-void residual (PVR) volume (PVR > 150 ml).
  • Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the investigator
  • Subject has an indwelling catheter or practices intermittent self catheterization.
  • Subject has evidence of a UTI.
Show all 20Show fewer
  • Subject has chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs
  • Subject has moderate to severe hepatic impairment
  • Subject has severe renal impairment or End Stage Renal disease
  • Subject has a clinically significant abnormal Electrocardiogram (ECG)
  • Subject has a concurrent malignancy or history of cancer (except noninvasive skin cancer) within the last 5 years prior to screening.
  • Subject has a QTcF interval > 450 ms for males or > 470 ms for females or is at risk of QT prolongation (e.g., family history of long QT syndrome, hypokalaemia).
  • Subject has received intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin.
  • Subject has severe uncontrolled hypertension, which is defined as a sitting average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg.
  • Main Exclusion at Randomization (visit 3):
  • Subject has achieved 100% continence from Visit 2 to Visit 3 (no incontinence episodes are recorded in the 3 day diary administered for 3 days prior to Visit 3).
  • Subject does not desire an increase in study medication.
  • Subject has an average total daily urine volume > 3000ml as recorded in the micturition diary.
  • Subject has severe uncontrolled hypertension, which is defined as a sitting average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg.
  • Subject has a clinically significant abnormal ECG

Trial locations and contacts

219 sites in 31 countries.

219 sites in 31 countries

United States36 sites
  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico, 87102

  • Alexandria Clinical Research

    Alexandria, Virginia, 22304

  • Brooklyn Urology Research Group

    Brooklyn, New York, 11215

  • Meridien Research

    Brooksville, Florida, 33016

  • Associated Pharmaceutical Research Center, Inc.

    Buena Park, California, 90620

  • PMG Research of Raleigh, dba PMG Research of Cary

    Cary, North Carolina, 27518

  • The Urology Group

    Cincinnati, Ohio, 45212

  • Innovative Research of West FL

    Clearwater, Florida, 33756

  • North Idaho Urology

    Coeur d'Alene, Idaho, 83814

  • Providence Health Partners

    Dayton, Ohio, 45439

  • Advanced Urology Centers of New York

    Garden City, New York, 11530

  • Alliance Urology Specialists

    Greensboro, North Carolina, 27403

  • Best Quality Research Inc.

    Hialeah, Florida, 33016

  • Palmetto Professional Research

    Hialeah, Florida, 33016

  • MedStar Health Research Institute

    Hyattsville, Maryland, 20782

  • First Urology, PSC

    Jeffersonville, Indiana, 47130

  • The Clinical Trial Center

    Jenkintown, Pennsylvania, 19046

  • Beyer Research

    Kalamazoo, Michigan, 49009

  • Premier Medical Group of the Hudson Valley PC

    Kingston, New York, 12401

  • Urology Center of Central Florida

    Kissimmee, Florida, 34741

  • The American Institute of Research

    Los Angeles, California, 90017

  • Deaconess Gateway Health Center

    Newburgh, Indiana, 47630

  • Quality Clinical Research

    Omaha, Nebraska, 68114

  • Premier Medical Group of the Hudson Valley PC

    Poughkeepsie, New York, 12601

  • Wake Research Associates LLC

    Raleigh, North Carolina, 27612

  • Health Concepts

    Rapid City, South Dakota, 57702

  • Jean Brown Research

    Salt Lake City, Utah, 84124

  • Meridian Clinical Research, LLC

    Savannah, Georgia, 31406

  • Herman Clinical Research

    Suwanee, Georgia, 30024

  • Meridien Research

    Tampa, Florida, 33606

  • Stedman Clinical Trials

    Tampa, Florida, 33613

  • Genova Clinical Research

    Tucson, Arizona, 85704

  • Bayview Research Group

    Valley Village, California, 91607

  • Bay State Clinical Trials, Inc.

    Watertown, Massachusetts, 02472

  • Private Practice

    West Palm Beach, Florida, 33407

  • PMG Research of Winston-Salem, LLC

    Winston-Salem, North Carolina, 27103

Other trials in United States

Russia14 sites
  • Site: 70003

    Moscow

  • Site: 70004

    Moscow

  • Site: 70005

    Moscow

  • Site: 70008

    Moscow

  • Site: 70010

    Moscow

  • Site: 70011

    Moscow

  • Site: 70012

    Moscow

  • Site: 70024

    Moscow

  • Site: 70013

    Rostove-on-Don

  • Site: 70002

    Saint Petersburg

  • Site: 70006

    Saint Petersburg

  • Site: 70007

    Saint Petersburg

  • Site: 70009

    Saint Petersburg

  • Site: 70025

    Saratov

Other trials in Russia

Canada12 sites
  • Site: 15001

    Barrie

  • Site: 15009

    Bathurst

  • Site: 15006

    Brampton

  • Site: 15015

    Granby

  • Site: 15014

    Kelowna

  • Site: 15007

    Kitchener

  • Site: 15019

    Sherbrooke

  • Site: 15012

    Toronto

  • Site: 15013

    Toronto

  • Site: 15016

    Victoria

  • Site: 15047

    Victoria

  • Site: 15018

    Victoriaville

Other trials in Canada

Spain12 sites
  • Site: 34012

    Barcelona

  • Site: 34016

    Bilbao

  • Site: 34013

    Donostia / San Sebastian

  • Site: 34001

    Getafe (Madrid)

  • Site: 34004

    Madrid

  • Site: 34015

    Madrid

  • Site: 34023

    Mendaro

  • Site: 34021

    Miranda de Ebro

  • Site: 34018

    San Sebastián de los Reyes

  • Site: 34007

    Seville

  • Site: 34020

    Seville

  • Site: 34014

    Vigo

Other trials in Spain

United Kingdom12 sites
  • Site: 44007

    Bristol

  • Site: 44012

    Cambridge

  • Site: 44015

    Cheltenham

  • Site: 44019

    Coventry

  • Site: 44009

    Garston

  • Site: 44016

    Kings Lynn

  • Site: 44017

    London

  • Site: 44018

    Northampton

  • Site: 44010

    Nottingham

  • Site: 44008

    Plymouth

  • Site: 44013

    Taunton

  • Site: 44011

    West Yorkshire

Other trials in United Kingdom

Austria11 sites
  • Site: 43008

    Graz

  • Site: 43001

    Innsbruck

  • Site: 43006

    Innsbruck

  • Site: 43007

    Linz

  • Site: 43002

    Vienna

  • Site: 43004

    Vienna

  • Site: 43005

    Vienna

  • Site: 43010

    Vienna

  • Site: 43011

    Vienna

  • Site: 43012

    Vienna

  • Site: 43003

    Wels

Other trials in Austria

Germany11 sites
  • Site: 49008

    Bad Ems

  • Site: 49022

    Berlin

  • Site: 49003

    Eisleben Lutherstadt

  • Site: 49021

    Hagenow

  • Site: 49011

    Halle

  • Site: 49004

    Hamburg

  • Site: 49018

    Henningsdorf

  • Site: 49009

    Hettstedt

  • Site: 49017

    Koblenz

  • Site: 49020

    Reutlingen

  • Site: 49014

    Sangerhausen

Other trials in Germany

Czechia10 sites
  • Site: 42015

    Brno

  • Site: 42020

    Mělník

  • Site: 42018

    Náchod

  • Site: 42004

    Pilsen

  • Site: 42021

    Pilsen

  • Site: 42007

    Prague

  • Site: 42008

    Prague

  • Site: 42016

    Prague

  • Site: 42017

    Prague

  • Site: 42022

    Prague

Other trials in Czechia

Belgium8 sites
  • Site: 32007

    Anderlecht

  • Site: 32013

    Deurne

  • Site: 32009

    Edegem

  • Site: 32003

    Ghent

  • Site: 32005

    Ghent

  • Site: 32015

    Kortrijk

  • Site: 32008

    Liège

  • Site: 32014

    Roeselare

Other trials in Belgium

Ireland8 sites
  • Site: 35303

    Cork

  • Site: 35301

    Dublin

  • Site: 35309

    Dublin

  • Site: 35310

    Dublin

  • Site: 35306

    Limerick

  • Site: 35313

    Mullingar

  • Site: 35304

    Tralee

  • Site: 35305

    Waterford

Other trials in Ireland

Romania7 sites
  • Site: 40016

    Bucharest

  • Site: 40018

    Bucharest

  • Site: 40012

    Craiova

  • Site: 40019

    Craiova

  • Site: 40003

    Judetul Ilfov

  • Site: 40017

    Oradea

  • Site: 40020

    Timișoara

Other trials in Romania

Slovakia7 sites
  • Site: 42110

    Bratislava

  • Site: 42114

    Košice

  • Site: 42113

    Michalovce

  • Site: 42111

    Nové Zámky

  • Site: 42112

    Piešťany

  • Site: 42108

    Poprad

  • Site: 42109

    Žilina

Other trials in Slovakia

Turkey (Türkiye)7 sites
  • Site: 90005

    Ankara

  • Site: 90008

    Ankara

  • Site: 90002

    Izmir

  • Site: 90003

    Izmir

  • Site: 90007

    Kocaeli

  • Site: 90004

    Manisa

  • Site: 90006

    Sivas

Other trials in Turkey (Türkiye)

Israel6 sites
  • Site: 97201

    Haifa

  • Site: 97202

    Jerusalem

  • Site: 97207

    Kfar Saba

  • Site: 97203

    Petah Tikva

  • Site: 97205

    Petah Tikva

  • Site: 97206

    Tel HaShomer

Other trials in Israel

Italy6 sites
  • Site: 39007

    Avellino

  • Site: 39002

    Cantanzaro

  • Site: 39010

    Florence

  • Site: 39006

    Perugia

  • Site: 39013

    Treviglio (BG)

  • Site: 39009

    Varese

Other trials in Italy

Poland6 sites
  • Site: 48002

    Kolbuszowa Dolna

  • Site: 48006

    Krakow

  • Site: 48010

    Lublin

  • Site: 48005

    Piaseczno

  • Site: 48001

    Warsaw

  • Site: 48008

    Warsaw

Other trials in Poland

Portugal6 sites
  • Site: 35104

    Lisbon

  • Site: 35105

    Lisbon

  • Site: 35102

    Matosinhos Municipality

  • Site: 35103

    Porto

  • Site: 35101

    Setúbal

  • Site: 35106

    Tomar

Other trials in Portugal

Sweden6 sites
  • Site: 46004

    Halmstad

  • Site: 46013

    Lund

  • Site: 46014

    Norrtälje

  • Site: 46001

    Stockholm

  • Site: 46012

    Stockholm

  • Site: 46015

    Umeå

Other trials in Sweden

Hungary5 sites
  • Site: 36003

    Csongrád

  • Site: 36011

    Hajdúszoboszló

  • Site: 36002

    Nyíregyháza

  • Site: 36008

    Salgótarján

  • Site: 36009

    Szekszárd

Other trials in Hungary

Denmark4 sites
  • Site: 45008

    Aarhus N

  • Site: 45003

    Frederiksberg

  • Site: 45009

    Herlev

  • Site: 45011

    Odense C

Other trials in Denmark

Slovenia4 sites
  • Site: 38601

    Ljubljana

  • Site: 38606

    Maribor

  • Site: 38607

    Maribor

  • Site: 38610

    Ptuj

Other trials in Slovenia

Armenia3 sites
  • Site: 37402

    Yerevan

  • Site: 37403

    Yerevan

  • Site: 37405

    Yerevan

Other trials in Armenia

Australia3 sites
  • Site: 61006

    Adelaide

  • Site: 61001

    Kogarah, Sydney

  • Site: 61016

    Victoria

Other trials in Australia

Greece3 sites
  • Site: 30001

    Athens

  • Site: 30005

    Heraklion, Crete

  • Site: 30002

    Pátrai

Other trials in Greece

Norway3 sites
  • Site: 47005

    Bekkestua

  • Site: 47002

    Tønsberg

  • Site: 47003

    Trondheim

Other trials in Norway

Finland2 sites
  • Site: 35804

    Helsinki (hus)

  • Site: 35805

    Tampere

Other trials in Finland

France2 sites
  • Site: 33018

    Bordeaux

  • Site: 33017

    Marseille

Other trials in France

Switzerland2 sites
  • Site: 41008

    Baden

  • Site: 41001

    Frauenfeld

Other trials in Switzerland

Georgia1 site
  • Site: 99502

    Tbilisi

Other trials in Georgia

Lebanon1 site
  • Site: 96101

    Beirut

Other trials in Lebanon

Netherlands1 site
  • Site: 31008

    Amsterdam

Other trials in Netherlands

About this study

Official title: A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms

The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.

Being tested
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo
Keywords
Vesitrim, Betanis, Urgency, Frequency, Mirabegron, YM178, Betmiga, Vesicare, Micturition, YM905, Solifenacin, Urinary incontinence, Overactive Bladder (OAB), Myrbetriq, Vesikur, Urgency incontinence
Medical subject headings
Urinary Bladder Diseases, Urinary Bladder, Overactive, Urologic Diseases, Urinary Incontinence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • mirabegron 25 mgDrug

    Also called Betmiga, Myrbetriq, YM178, Betanis

    Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

  • mirabegron 50 mgDrug

    Also called YM905, Vesitrim, Vesikur, Vesicare

    Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 5 mgDrug

    Also called Vesicare, Vesitrim, YM905, Vesikur

    Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 10 mgDrug

    Also called Vesicare, Vesitrim, YM905, Vesikur

    Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.

  • mirabegron 25 mg matching placeboDrug

    Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

  • mirabegron 50 mg matching placeboDrug

    Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 5 mg matching placeboDrug

    Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

  • solifenacin 10 mg matching placeboDrug

    Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Study groups in NCT01908829
Study groupRoleWhat they receive
Combination (solifenacin + mirabegron)ExperimentalParticipants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
Receives: Drug: mirabegron 25 mg; Drug: mirabegron 50 mg; Drug: solifenacin 5 mg; Drug: solifenacin 10 mg matching placebo
Solifenacin 5 mgActive comparatorParticipants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
Receives: Drug: solifenacin 5 mg; Drug: mirabegron 25 mg matching placebo; Drug: mirabegron 50 mg matching placebo; Drug: solifenacin 10 mg matching placebo
Solifenacin 10 mgActive comparatorParticipants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
Receives: Drug: solifenacin 10 mg; Drug: mirabegron 25 mg matching placebo; Drug: mirabegron 50 mg matching placebo; Drug: solifenacin 5 mg matching placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours

    The mean number of incontinence episodes (complaint of any involuntary leakage of urine) per day was derived from number of incontinence episodes recorded on valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period. The analysis population consisted of the Full Analysis Set (FAS) which comprised of all the Randomized Analysis Set's (RAS) participants who met the following criteria: took at least 1 dose of double-blind study drug after randomization, reported at least 1 micturition in the baseline diary \& at least 1 micturition postbaseline \& reported at least 1 incontinence episode in the baseline diary. For participants who withdrew before EoT (week 12) and have no measurement available for that diary period, the Last Observation Carried Forward (LOCF) value during the double-blind study period was used as EoT value to derive the primary variable.

    Measured: Baseline and end of treatment (up to 12 weeks)

Secondary outcomes (35)
  1. Change From Baseline to Weeks 4, 8 & 12 in Mean Number of Incontinence Episodes Per 24 Hours

    The mean number of incontinence episodes (complaint of any involuntary leakage of urine) per day was derived from number of incontinence episodes recorded on valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period.

    Measured: Baseline and weeks 4, 8 & 12

  2. Change From Baseline in Mean Number of Micturitions Per 24 Hours

    The average number of micturitions (voluntary urinations (excluding incontinence only episodes)) per 24 hours was derived from number of micturitions recorded on valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period (excluding incontinence only episodes).

    Measured: Baseline and weeks 4, 8 & 12

  3. Number of Incontinence Episodes Reported During the 3-Day Diary

    The number of incontinence episodes (complaint of any involuntary leakage of urine) per day was derived from total number of incontinence episodes on valid diary days recorded during the 3-day micturition diary period.

    Measured: Weeks 4, 8 and 12

  4. Change From Baseline in Mean Volume Voided (MVV) Per Micturition

    MVV per micturition was defined as MVV (mL) per micturition during last 3 days of the 3-day micturition diary period. MVV per micturition was calculated as the sum of each volume voided for each record with volume voided > 0 on valid diary days divided by the total number of records with a volume voided > 0 on valid diary days during the 3-day micturition diary period.

    Measured: Baseline and weeks 4, 8 & 12

  5. Change From Baseline to EoT in Corrected Micturition Frequency (CMF)

    CMF was defined as the mean number of micturitions per 24 hours that participants would have at EoT if their fluid intake had remained unchanged since baseline. This was calculated by the MVV per Micturition at baseline multiplied by the mean number of micturitions per 24 hours at baseline divided by the MVV per micturition at EoT.

    Measured: Baseline and EoT (up to 12 weeks)

  6. Change From Baseline in Mean Number of Urgency Incontinence (UI) Episodes Per 24 Hours

    UI was defined as the complaint of involuntary urine leakage accompanied by or immediately preceded by urgency. UI was measured using the Patient Perception of Intensity of Urgency Scale (PPIUS), a patient reported outcome validated 5-point categorical scale rating the degree of associated urinary urgency severity (0=No urgency, I felt no need to empty my bladder, but did so for other reasons. 1=Mild, I could postpone voiding as long as necessary, without fear of wetting myself. 2= Moderate, I could postpone voiding for a short while, without fear of wetting myself. 3=Severe, I could not postpone voiding, but had to rush to the toilet in order not to wet myself. 4=Urgency incontinence, I leaked before arriving to the toilet). One urgency incontinence episode was counted for each record of the diary in which the following occurred: incontinence episode or 'both' was recorded \& severity of urinary urgency recorded was 3 or 4.

    Measured: Baseline and weeks 4, 8 & 12

  7. Number of UI Episodes Reported During the 3-Day Diary

    Number of UI episodes was calculated using the number of UI episodes recorded on valid diary days during the 3-day micturition diary period. NOTE: Only urgency incontinence episodes recorded on a valid diary day were counted.

    Measured: Weeks 4, 8 and 12

  8. Change From Baseline in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours

    An urgency episode was defined as the complaint of a sudden, compelling desire to pass urine, which is difficult to defer. The mean number of urgency episodes (severity of 3 or 4) per 24 hours was defined as the average number of times a participant recorded an urgency episode (severity of 3 or 4) with or without incontinence per day during the 3-day micturition diary period. Measured using the PPIUS scale. This was calculated using the sum of each record with an urgency episode (severity of 3 or 4) recorded on a valid diary day divided by the number of valid diary days during the 3-day micturition diary period.

    Measured: Baseline and weeks 4, 8 & 12

  9. Change From Baseline in Mean Number of Pads Per 24 Hours

    The mean number of pads per 24 hours was defined as the average number of times a participant recorded a new pad used per day during the 3-day micturition diary period. This was calculated using the number of new pads used during valid diary days during the 3-day micturition diary period divided by the number of valid diary days during the 3-day micturition diary period.

    Measured: Baseline and weeks 4, 8 & 12

  10. Number of Pads Used During the 3-Day Diary

    The number of pads used was defined as the number of times a participant recorded a new pad used during the 3-day micturition diary period. This was calculated using the sum of each record with new pad checked. Only records with new pad checked on a valid diary day were counted.

    Measured: Weeks 4, 8 and 12

  11. Change From Baseline in Mean Number of Nocturia Episodes

    Mean number of nocturia episodes was defined as the number of times a participant urinated (excluding incontinence only episodes) while sleeping during the 3-day diary period, divided by the number of valid diary days during the diary period. Night time episode of incontinence only was not considered a nocturia episode. Nocturia episodes were counted for each micturition record which occurred between the date/time of going to bed with intention to sleep and the date/time of getting up with intention to stay awake on a valid diary day \& which was accompanied by a sleep interruption. Nocturia only determined for those who were not night-shift workers.

    Measured: Baseline and weeks 4, 8 & 12

  12. Number of Nocturia Episodes Reported Over 3-Day Diary

    The number of nocturia episodes was defined as the number of times a participant urinated (excluding incontinence only episodes) during sleeping time during the 3-day micturition diary period. This was calculated using the sum of each nocturia episode recorded on valid diary days during the 3-day micturition diary period.

    Measured: Weeks 4, 8 and 12

  13. Number of Participants With Change From Baseline to EoT in Euroqol European Quality of Life-5 Dimensions (EQ-5D) Subscale Score: Mobility

    The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.

    Measured: Baseline and EoT (up to 12 weeks)

  14. Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Self-care

    The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.

    Measured: Baseline and EoT (up to 12 weeks)

  15. Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Usual Activities

    The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.

    Measured: Baseline and EoT (up to 12 weeks)

  16. Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Pain/Discomfort

    The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.

    Measured: Baseline and EoT (up to 12 weeks)

  17. Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Anxiety/Depression

    The EQ-5D is an international, standardized, nondisease specific instrument for describing and valuing health status. It has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels: level 1=no problem or none; level 2=slight problems; level 3=moderate problems; level 4=severe problems; level 5=unable to perform activity.

    Measured: Baseline and EoT (up to 12 weeks)

  18. Change From Baseline in Overactive Bladder Symptom (OAB-q) Symptom Bother Score

    The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). Symptom Bother score ranges from 0 (least severity) to 100 (worst severity).

    Measured: Baseline and weeks 4, 8 & 12

  19. Change From Baseline in OAB-q Health-Related Quality of Life (HRQL) Total Score

    The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).

    Measured: Baseline and weeks 4, 8 & 12

  20. Change From Baseline in OAB-q HRQL Subscale Score: Coping

    The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).

    Measured: Baseline and weeks 4, 8 & 12

  21. Change From Baseline in OAB-q HRQL Subscale Score: Concern

    The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).

    Measured: Baseline and weeks 4, 8 & 12

  22. Change From Baseline in OAB-q HRQL Subscale Score: Sleep

    The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).

    Measured: Baseline and weeks 4, 8 & 12

  23. Change From Baseline in OAB-q HRQL Subscale Score: Social Interaction

    The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).

    Measured: Baseline and weeks 4, 8 & 12

  24. Change From Baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) Score

    The TS-VAS rated participant satisfaction with treatment on a scale from 0 (No, not at all) to 10 (Yes, completely).

    Measured: Baseline and weeks 4, 8 & 12

  25. Change From Baseline in Patient Perception Bladder Control (PPBC) Score

    The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. PPBC score: 1-no problem, 2- some very minor problems, 3-some minor problems, 4-moderate problems, 5-severe problems, 6-many severe problems.

    Measured: Baseline and weeks 4, 8 & 12

  26. Number of Participants in Each Category of Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)

    The PGIC was a 2-part questionnaire, assessing both the change in the participant's overall condition (Patient Impression in General Health (PIBS)) and change in bladder condition since the start of the study (Patient Impression in General Health (PIGH)) (from very much worse to very much improved). The CGIC was a single questionnaire assessing the participant's change in bladder condition since the beginning of the study (Clinician Impression in Bladder Symptoms (CIBS)).

    Measured: End of treatment (up to 12 weeks)

  27. Percentage of Participants With at Least a 50% Decrease From Baseline in Mean Number of Incontinence Episodes Per 24 Hours

    Incontinence was defined as any involuntary leakage of urine.

    Measured: Weeks 4, 8 and 12

  28. Percentage of Participants With Zero Incontinence Episodes Postbaseline

    Incontinence was defined as any involuntary leakage of urine.

    Measured: Weeks 4, 8 and 12

  29. Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline

    Micturitions were defined as voluntary urinations (excluding incontinence only episodes).

    Measured: Weeks 4, 8 and 12

  30. Percentage of Participants With at Least a 10-Point Improvement From Baseline in OAB-q Symptom Bother Score

    The OAB-q was a self-reported questionnaire comprising 33-items each rated on a 6-point Likert scale. The questionnaire consisted of an 8-item symptom bother scale and 25 health-related QoL (HRQL) items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction). Symptom Bother score ranges from 0 (least severity) to 100 (worst severity).

    Measured: Weeks 4, 8 and 12

  31. Percentage of Participants With at Least a 10-Point Improvement From Baseline in HRQL Total Score

    HRQL subscales (coping, concern, sleep and social) and total score range from 0 (worst quality of life) to 100 (best quality of life).

    Measured: Weeks 4, 8 and 12

  32. Percentage of Participants With at Least a 1-Point Improvement From Baseline in PPBC

    The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition.

    Measured: Weeks 4, 8 and 12

  33. Percentage of Participants With Major (at Least 2-Point) Improvement From Baseline in PPBC

    The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition.

    Measured: Weeks 4, 8 and 12

  34. Number of Participants With Adverse Events (AEs)

    AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures \& which does not necessarily have a causal relationship with this treatment. Treatment-Emergent Adverse Event (TEAE) referred to an adverse event which started or worsened in the period from first double-blind medication intake until 30 days after the last double-blind medication intake.

    Measured: From first dose of double blind treatment until 30 days after last dose (up to 16 weeks)

  35. Change From Baseline in Post Void Residual (PVR) Volume

    PVR Volume was assessed by bladder scan.

    Measured: Baseline and weeks 4, 8 & 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jul 2013 (estimated)
  2. Study start10 Jul 2013
  3. Primary completion24 Nov 2014
  4. Study completion25 Nov 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
2,174 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01908829
Sponsor's protocol ID
905-EC-012
Other IDs
2012-005401-41
Acronym
BESIDE
Status last verified
Oct 2024
First submitted
24 Jul 2013
Last updated
31 Oct 2024
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Publications

  • Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stolzel M, Choudhury N, Drake MJ. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus. 2017 Dec;3(6):629-638. doi: 10.1016/j.euf.2017.08.008. Epub 2017 Sep 12.

    PubMed 28916436
  • Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stolzel M, Herholdt C, MacDiarmid S; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8.

    PubMed 26965560

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing mirabegron 25 mg, mirabegron 50 mg and solifenacin 5 mg in people with Urinary Bladder Diseases and Urinary Bladder Overactive, run by Astellas Pharma Europe Ltd. at 219 sites in 31 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 219 sites in United States, Russia, Canada, Spain, United Kingdom and 26 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Oct 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours (time frame: Baseline and end of treatment (up to 12 weeks)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01908829, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in